Is Rallybio Corporation Common Stock a good investment? Rallybio Corporation Common Stock (RLYB) is currently trading at 15.78 USD.
In terms of valuation, the stock trades at a P/E ratio of 3.41. This relatively low multiple may signal that Rallybio Corporation Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Rallybio Corporation Common Stock is expected to release its next earnings report on March 11, 2027. The market consensus estimate for Forward EPS is -5.40.
No, it does not currently pay a dividend.
Rallybio Corporation Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be March 11, 2027. The company currently has a trailing EPS of 4.61.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
| Year | Total Dividends |
|---|---|
| ▸2026 |
41.36 USD
|
| Nov. 30, 2026 | 27.8000 |
| Nov. 13, 2026 | 13.5600 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Rallybio Corporation Common Stock | Nov 30, 2026 | Upcoming | 27.8 USD |
| Rallybio Corporation Common Stock | Nov 13, 2026 | Paid | 13.56 USD |
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 6, 2026 | 1:8 |
Community Discussion